Our Team

Shuang Liu, PhD

Managing Member

Current CEO and Founder of ConSynance Therapeutics, a CNS/Rare-Disease company with a focus on Prader-Willi syndrome. Shuang is a scientist and entrepreneur with 25+ years of experience in drug R&D. Prior to ConSynance, Shuang led discovery teams at Curia to deliver multiple NCEs into clinical trials.

Shuang holds a Ph.D. in Organic Chemistry from the University of Georgia.

John Maki

Managing Partner

Currently CEO and Founder of Bayesian Biotech, a personalized precision medicine company focused on rare pediatric diseases. Previous roles held by John include President of ConSynance, CEO of Vicus Therapeutics (aneuro-immuno-oncology company), Managing Director of TDI and Audax Group, Principal of Bain Capital and Consultant at Bain & Company. John also serves on Board of Trustees of BioNJ and Chair of the AI Committee.

John holds an A.B from Harvard.

Bob Smith

Member

Former Senior VP of Gene Therapy & Rare Disease and Commercial Strategy & Innovation at Pfizer, Bob has 30+ years of experience including alliance management, business development, and R&D. His career is marked by significant roles in global M&A, BD, and contributions to various business units. Bob is the board member of multiple companies and industry associations.

Bob holds a BS in Neuroscience and an MBA from the University of Rochester.

Clinical & Scientific Advisors

Robin Spiller, MD

Michael Silverman, MD, FACP

Prof. of Gastroenterology, Nottingham Digestive Diseases Unit School of Medicine, Univ. of Nottingham.

Dr. Spiller's main interest is in the pathophysiology of functional GI diseases, particularly focusing on the role of infection, inflammation and alterations in serotonin metabolism in IBS. He has twice edited the British Society of Gastroenterology (BSG) Guidelines for the management of IBS and is a member of the Board of the Rome Foundation, an international group that sets the criteria for the classification of functional GI diseases. He is the author of more than 335 scientific publications.

Michael Silverman, MD, FACP

President of BioStrategicsConsulting.

Dr. Silverman is a board-certified internist with over 3 decades of experience in biopharmaceutical industry clinical research, product development, and strategic planning. His pharmaceutical industry career has included positions of increasing responsibility at both global and start-up companies, where he has managed multiple pharmaceutical and biotechnology projects across a broad scope of therapeutic areas. Dr. Silverman was the medical monitor of the Phase I study of STX-101.

Led by an industry-leading team of scientists, physicians, & executives, Serotonix draws from a diverse tapesty of expertise to bring life-changing therapies to patients living with GI disorders

Management Team

Shuang Liu, PhD

John Maki

Bob Smith

Clinical & Scientific Advisors

Robin Spiller, MD

Michael Silverman, MD, FACP

Michael Silverman, MD, FACP

Michael Silverman, MD, FACP

Michael Silverman, MD, FACP

Michael Silverman, MD, FACP

Led by an industry-leading team of scientists, physicians, & executives, Serotonix draws from a diverse tapesty of expertise to bring life-changing therapies to patients living with GI disorders

Management Team

Shuang Liu, PhD

John Maki

Bob Smith

Clinical & Scientific Advisors

Robin Spiller, MD

Michael Silverman, MD, FACP

Michael Silverman, MD, FACP

Michael Silverman, MD, FACP

Michael Silverman, MD, FACP

Michael Silverman, MD, FACP

This website uses cookies.